Hepatocyte growth factor (HGF) and its receptor (c-Met) are associated with cancer cell motility and invasiveness. p21-activated kinase 4 (PAK4), a potential therapeutic target, is recruited to and activated by c-Met. In response, PAK4 phosphorylates LIM kinase 1 (LIMK1) in an HGF-dependent manner in metastatic prostate carcinoma cells. PAK4 overexpression is known to induce increased cell migration speed but the requirement for kinase activity has not been established. We have used a panel of PAK4 truncations and mutations in a combination of overexpression and RNAi rescue experiments to determine the requirement for PAK4 kinase activity during carcinoma cell motility downstream of HGF. We find that neither the kinase domain alone nor a PAK4 mutant unable to bind Cdc42 is able to fully rescue cell motility in a PAK4-deficient background. Nevertheless, we find that PAK4 kinase activity and associated LIMK1 activity are essential for carcinoma cell motility, highlighting PAK4 as a potential anti-metastatic therapeutic target. We also show here that overexpression of PAK4 harbouring a somatic mutation, E329K, increased the HGF-driven motility of metastatic prostate carcinoma cells. E329 lies within the glycine-rich loop region of the kinase. Our data suggest that E329K mutation leads to a modest increase in kinase activity, conferring resistance to competitive ATP inhibitors in addition to promoting cell migration. The existence of such a mutation may have implications for the development of PAK4-specific competitive ATP inhibitors should PAK4 be further explored for clinical inhibition.
INTRODUCTION
The progression of cancer by oncogenic transformation from localised primary solid tumours to more widely disseminated metastasis is associated with poor patient prognosis and increased mortality. As such, regulators of metastatic cell migration represent attractive therapeutic targets. The oncogenic receptor tyrosine kinase c-Met represents such a target for cancer therapeutics because it has a dual role promoting tumour formation in addition to stimulating cell motility and metastasis. 1 Indeed a variety of c-Met-targeting agents are currently under evaluation in clinical trials. 2 Activation of c-MET by hepatocyte growth factor (HGF) leads to recruitment of a plethora of proteins including Gab-1. 3 Recently, p21-activated kinase 4 (PAK4) was identified as a novel Gab-1-binding partner. 4 PAK4 is a group II PAK that specifically interacts with Cdc42. 5 However, the regulation of PAK4 activity and the role of Cdc42 interaction is poorly understood. It is known that PAK4 binds and phosphorylates a number of cytoskeletal protein targets including GEF-H1, 6 paxillin, 7 b5 integrin 8 and the ADF/cofilin regulators LIM kinase 1 (LIMK1) and slingshot homologue (SSH-1). 9, 10 Cofilin activity is important for supporting lamellipodia protrusion by promoting F-actin disassembly 11 and its regulation has been implicated in promoting and directing cancer cell motility. 12 PAK4 is tumorigenic in vitro and in vivo 13, 14 and overexpression or genetic amplification of PAK4 occurs in numerous cancer cell lines and tumours (reviewed in Whale et al. 15 ). Further, two somatic mutations adjacent to and within the PAK4 kinase domain (A279T and E329K) have been identified in colon carcinoma patients; 16 although the functional consequences of these mutations has not been explored. Several recent studies have also implicated PAK4 in pancreatic, breast and ovarian carcinoma cell invasion. 17, 18, 19 There is currently much interest in targeting group II PAKs therapeutically (reviewed by Eswaran et al. 20 and Zhao and Manser 21 ). Indeed, a PAK4-targeting competitive ATP inhibitor, PF-3758309, has been reported. 22 However, whether PAK4 promotes motility via kinase-dependent or -independent mechanisms has not been addressed. In this study, we used a systematic approach to study domains of PAK4 required for HGF signal transduction in a prostate carcinoma cell model of motility.
RESULTS AND DISCUSSION
PAK4 is required for HGF-induced LIMK1-mediated PC3 cell migration To facilitate our investigation, we have used PC3 cells, which do not form cell:cell junctions or prominent actin stress fibres. We generated stable cell lines expressing control non-targeting or PAK4-specific short hairpin RNA (shRNA) and turbo green fluorescent protein from a bicistronic operon. There is a B80% reduction in PAK4 expression in cells stably expressing PAK4 shRNA, without affecting PAK1, PAK2, PAK6 or HGFR/c-Met expression ( Figure 1a and Supplementary Figure S1A ). We found that depletion of PAK4 significantly reduced cell motility in response to HGF (control shRNA cell mean speed±s.e.m. 0.38 ± 0.018 mM/min; PAK4 shRNA cell mean speed ± s.e.m. 0.26 ± 0.011 mM/min; Po0.0001) (Figure 1b , Supplementary movies 1 and 2). These results are consistent with previous reports using PAK4 null fibroblasts 23 and our previous data. 24 Indeed, similar data have also implicated PAK4 in pancreatic ductal adenocarcinoma, breast and ovarian carcinoma cell invasion, although these studies have tended to rely on transwell assays that preclude microscopic observation of motile cells and involve subjective measurement rather than directly measuring cell migration speed. 17, 18, 19 We have previously shown that PC3 cells migrate up a linear gradient of HGF. 24 Here we find that PAK4depleted PC3 cells exhibit positive chemotaxis (Figure 1c) , albeit moving at a reduced mean speed of migration (mean speed±s.e.m. 0.17 ± 0.010 mM/min), thus knockdown of PAK4 attenuates the mean speed of migration, but not the directionality of PC3 cell motility. As a further control, we transiently transfected PAK4 knockdown cells with shRNA-resistant mRFP-tagged PAK4 (PAK4r 8 ). Crucially, mRFP-PAK4r was able to rescue the mean Figure 1 . PAK4 is required for HGF-mediated cell motility, but not chemotaxis. (a) For western blot analysis, cells were lysed in all experiments as follows: 10 min in lysis buffer (0.5% NP-40, 30 mM sodium pyrophosphate, 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1 mM EDTA, 50 mM NaF, 1 mM Na 3 VO 4 and complete mini-EDTA free protease inhibitor (Roche, Welwyn, UK), then clarification by centrifugation at 14 000 g for 10 min. Lysates were immunoblotted according to the standard procedures. Blots were developed by enhanced chemiluminescence (ECLplus, GE Healthcare, Little Chalfont, UK). Control and PAK4 shRNA-expressing cell lysates were probed for PAK4/6/1/2, c-Met, turbo green fluorescent protein and glyceraldehydes-3 phosphate dehydrogenase (GAPDH) (for details of antibodies see Supplementary Materials and Methods). PAK4 expression from cell lysates stably expressing control and PAK4 shRNA from four independent experiments were quantified relative to control ± s.d. (b, d) PC3 cells stably expressing control and PAK4 shRNA were maintained in low serum for 24 h, stimulated with HGF and imaged or PC3 cells stably expressing PAK4 shRNA were transfected with plasmids encoding mRFP or mRFP-PAK4r and serum starved for 24 h. Cells were then stimulated with HGF in the presence of either dimethyl sulfoxide or LIMK inhibitor and imaged. Cell images were collected using an axiovert 100 microscope and Sensicam (PCO Cook, Kelheim, Germany) CCD camera, taking a frame every 10 min for 21 h using AQM acquisition software (Kinetic Imaging Ltd, Belfast, UK). Subsequently, cells were tracked for the whole of the time-lapse sequence using Motion Analysis software (Kinetic Imaging Ltd). Unless indicated, at least 50 cells were tracked over nine separate films from three separate experiments for each experimental condition. Mathematical analysis was then carried out using Mathematica 6.0 workbooks. 37 Mean track speeds for each condition were compared using the student's t-test and statistical significance was accepted for a minimum Pp0.05. See Supplementary Materials and Methods for details of migration analysis. (c) PAK4-depleted cells were maintained in low serum for 24 h, exposed to a gradient of HGF in a Dunn chemotaxis chamber for 12 h and individual cells (n ¼ 123) from two separate experiments tracked. A chemotaxis circular histogram was generated to show the proportion of cells with a direction of migration lying within each 181 segment (source of HGF at the top). Arrow indicates mean direction of cell migration; grey segment 99% confidence interval calculated from a Rayleigh test. (e) Purified glutathione-S transferase (GST), GST-PAK4 kinase domain, GST-PAK4Dkinase and GST-PAK4DCRIB beads were used to pull down Myc-LIMK1 from cell lysates. Samples were analysed by anti-Myc immunoblotting and ponceau staining. Representative of three separate experiments. GST pull-down assays were performed according to the standard protocols, for details see Supplementary Materials and Methods.
speed of cell migration of PAK4-depleted cells (Figure 1d ). HGF stimulation of PC3 cells leads to PAK4-mediated phosphorylation and activation of LIMK, 24 therefore, we sought to determine if LIMK activity was required for PAK4-mediated migration. We incubated mRFP-PAK4r-rescued cells with N- 25 or dimethyl sulfoxide as a control. LIMK inhibitor inhibited HGF-induced PAK4r-mediated cell migration in a dose-dependent manner (Figure 1d ). These findings confirm a specific requirement for LIMK1 in PAK4-mediated HGFinduced cell motility. Several studies advocate a role for LIMK in promoting cell migration, 26 but our findings conflict with data using LIMK inhibitor on breast cancer cells where the authors suggested that LIMKs are not required for 2D cell motility, though are required for invasion. 25 The seeming discrepancy between these data is likely due to experimental design. Scott et al. 25 analysed the effect of LIMK inhibition of cells migrating in media containing serum on cell-derived matrices and as confluent monolayers in modified scratch assays, where multiple cues to stimulate cell migration exist. In our assays, the cells were serum starved prior to specific activation with HGF, compelling the cells to migrate in response to HGF using the preferential PAK4-LIMKcofilin pathway. 24 The kinase domain of PAK4 is sufficient for substrate interaction, but not motility Given that inhibiting LIMK impairs PAK4-mediated PC3 cell motility (Figure 1d ), we further explored the PAK4-LIMK1 interaction. Glutathione-S transferaseGST pull-down assays revealed that the C-terminal kinase domain of PAK4 is capable of binding to LIMK1 (Figure 1e ). Taken together with our LIMK inhibitor studies, this finding validates LIMK1 as a direct PAK4 target downstream of HGF. To test whether the kinase domain is sufficient to rescue the attenuated motility of PAK4-depleted cells, we expressed shRNA-resistant (Figures 2a-c) mRFP-tagged PAK4 kinase domain (mRFP-kinase, amino acids 324-591) and the N-terminus of PAK4 (mRFP-PAK4kinase, amino acids 1-323). mRFP-PAK4kinase and mRFP-kinase were not able to rescue the speed of cell migration of PAK4-depleted cells (Figure 2e ). In contrast, Li et al. 8 found that the PAK4 kinase domain (amino acids 323-591) was sufficient to promote haptotactic migration towards vitronectin. This difference in requirement for minimal PAK4 sequences might result from the fact that the b5 integrin-binding site is also within the PAK4 kinase domain, 27 whereas the PAK4 Gab-1-interaction domain required to recruit PAK4 to c-Met is not. 4 We found that PAK4 derivatives lacking the first 132 aminoacid residues were mislocalised to the nucleus, even if they retained the Gab-1-interaction domain (data not shown). Our finding agrees with a recent report that identified N-terminal sequences that mediate PAK4 nuclear localisation 27 and emphasises that sequences outside the kinase domain are required to correctly localise PAK4 during HGF signal transduction.
GTPase interaction and kinase activity are required for motility Because the N-terminus and the C-terminal kinase domain of PAK4 are both necessary to rescue cell migration of PAK4depelted cells, we considered whether both a GTPase interaction and a kinase activity were similarly both required to stimulate migration. To test this hypothesis, we introduced mutations in conserved histidine residues within the N-terminal CRIB domain (H19, 22L) and mutations to inactivate the kinase domain (K350 and 351M 5, 13 ) into both PAK4r (Figure 2a ) and 'wild-type' PAK4 ( Figure 4a ). We confirmed that PAK4 H19,22L and the PAK4 kinase domain are not able to bind constitutively active Cdc42 G12V (Figure 2d ). Further, we confirmed that both PAK4 H19,22L and PAK4 K350,351M mutants were able to bind LIMK1 (data not shown). In motility assays, we found that the Cdc42-deficient binding mutant PAK4 H19,22L was able to partially rescue motility of PAK4depleted cells (Figure 2e ), suggesting that interaction with Cdc42 is required for full motility. In contrast, kinase dead PAK4 K350,351M failed to rescue PAK4 depletion and PAK4-depleted cells expressing PAK4 K350,351M did not display any significant cell motility (Figure 2e ). The underlying mechanism of migration inhibition in this context is unclear but we could speculate that PAK4 K350,351M is acting to sequester substrate utilised by not only PAK4 but other kinases and thus inhibits the additional signalling pathways.
To complement our rescue experiments, we overexpressed PAK4 derivatives in cells to determine their ability to enhance HGF-mediated cell migration. Consistent with our previous findings, 24 overexpression of full-length (mRFP-) PAK4 significantly enhances HGF-mediated cell motility (Figure 3a-b) . mRFP-PAK4 H19, 22L ,-PAK4Kinase and -kinase domain, in contrast, failed to enhance HGF-mediated cell migration. However, once again we observed the most dramatic effect on cell motility by overexpressing PAK4 K350,351M (Figure 3b ), suggesting that PAK4 K350, 351M overexpression has a dominant negative effect on wild-type PC3 cells expressing endogenous PAK4. Siu et al. 19 also observed a similar inhibition of haptotactic transwell migration of breast carcinoma cells expressing kinase dead PAK4. We did not observe any alteration in the directional persistence of cells expressing mRFP or any of the mRFP-tagged PAK4 derivatives in our motility assays. Kinase dead PAK4 K350,351M -expressing cells exhibited a slight increase in persistent migration, though this is likely due to their diminished motility (Supplementary Figure 1B) . Taken together with the findings that PAK4 depletion attenuated cell motility in response to HGF and that removing the PAK4 kinase domain abolishes rescue of motility, we conclude that PAK4 kinase activity is critical for cell motility. These data confirm that inhibition of PAK4 kinase activity is an attractive therapeutic target in efforts to inhibit metastatic spread.
Somatic mutation E329K enhances PC3 cell motility
Having found clear evidence for the regulation of cell migration by the kinase domain of PAK4, we sought to determine how PAK4 somatic mutations 16 adjacent to and within the kinase domain would affect cell motility. To that end, we generated A279T and E329K mutations in PAK4 (Figure 3a ). mRFP-PAK4 A279T failed to enhance migration speed above the level of mRFP controls (Figure 3b ). Residue A279 lies within a PxxP sequence and it is tempting to speculate that the substitution of hydrophobic alanine to the larger and nucleophilic threonine might disrupt an SH3 domain interaction or even engage different SH3 domaincontaining proteins. From our data, it is not clear what advantage metastatic cells gain from the A279T mutation, but it might be proliferative rather than migratory. Neither expression of mRFP-PAK4, -PAK4 A279T or -PAK4 E329K effected the persistence of random cell migration (Supplementary Figure 1B) . However, we found that overexpression of mRFP-PAK4 E329K significantly enhanced mean migration speed (Figure 3b) , even beyond the level induced by overexpressing wild-type PAK4.
Mutation of E329K does not impair interaction with Cdc42, Gab-1 or LIMK1
To explore how E329K mutation influences PAK4 biology, we examined the location of this residue in the kinase domain crystal structure of PAK4. 22, 28 E329 resides on b strand 1b within the glycine-rich loop of the kinase, a conserved structural feature that contributes to ATP binding and orientation for catalysis. 29 The E329 side chain extends upward from the glycine-rich loop away from the bound ATP and is juxtaposed to the nearby basic side chain K326 at a distance indicative of a salt bridge interaction (Figure 3c ). In fact, glycine-rich loop salt bridges are a common feature in a large number of diverse protein kinases. 30 To determine whether this mutation affects binding to either upstream regulators (Cdc42/Gab-1) or substrates (LIMK1), we performed interaction assays. These assays revealed that similarly to PAK4, PAK4 E329K is able to interact with Cdc42, Gab-1 and LIMK1 (Figures 3d-f ).
Mutation of E329K elevates kinase activity
Mutation of glycine-rich loop amino-acid residues can have opposing effects on the catalytic activity of kinases; mutation can impair catalytic activity, as is the case for Lyn. 30 In contrast, mutation of E255 in Abl tyrosine kinase does not diminish catalytic activity 31, 32 and can modestly increase the transforming activity of Bcr-Abl fusion proteins. 33 We therefore sought to determine the activity of PAK E329K using an in vitro kinase assay. We found that PAK E329K retains autophosphorylation and substrate kinase activity (Figure 4a, lanes 1, 3 and 6) , moreover, there is a modest (and significant) increase in PAK E329K activity compared with wild-type PAK4 (Figures 4a-d ) These data show that PAK E329K is catalytically active in cells and suggest that PAK4 E329K -mediated increased cell migration speed is likely due to increased kinase activity, providing further evidence that there is a correlation between the level of PAK4 kinase activity and cell migration speed in PC3 cells (Figure 2e ). We did not find a significant difference between the K m (ATP) of wild-type PAK4 and PAK E329K (our unpublished data) but did confirm a small but significant difference in kinase activity using a luminescence assay (Supplementary Figure 1C) . K m (ATP) measurements do not distinguish between autophosphorylation and substrate phosphorylation and we would speculate that the increased activity we detect is centred on the interaction between PAK E329K and its substrates. Indeed, overexpression of PAK E329K increases the level of LIMK1 phosphorylation in cells compared with overexpression of wild-type PAK4 (Figure 4e ). The E329K mutation delivers an increase over wildtype level activity, which translates to approximately 10%. Although this number seems modest, previous work 7 has already shown that high levels of PAK4 kinase activity induce a loss of cell adhesion and rounding. Therefore, a 10% increase in kinase activity translated into an increased migration speed, as we have demonstrated here, is more likely to convey a metastatic advantage than high levels of kinase activity, where cellular function is likely to be significantly impaired. Indeed, this very mutation was found in a cancer patient sample. 16 Mutation of E329K confers resistance to competitive ATP inhibitors Bcr-Abl E255K or E255V mutations (analogous to the PAK4 E329K mutation) have been strongly implicated in clinical resistance to the competitive ATP inhibitor imatinib/gleevec 34, 35 in chronic myeloiod leukimia. We speculated that PAK4 E329K mutation might confer resistance to competitive ATP inhibitors. To test this, we performed in vitro kinase assays in the presence of purvalanol A 28 and PAK4i, both potent PAK4 inhibitors. 22 At 10 mM purvalanol A, we observed inhibition of both wild-type PAK4 and PAK4 E329K kinase activity (Figure 4a, lanes 5 and 8) . In the presence of 0.5 mM purvalanol A, PAK4 E329K appeared to exhibit a modest resistance to inhibition, exhibiting moderately elevated substrate phosphorylation in comparison with wild-type PAK4 (Figures 4a and b, lanes 4 and 7) . This effect was also evident in the presence of PAK4i. PAK4 E329K substrate phosphorylation in the presence of 1 mM PAK4i, in particular, was significantly higher than wild-type PAK4 (Figures 4c and d, lanes   4 and 7) . Moreover, this effect was not solely due to the incorporation of a point mutation in the kinase domain, as glutathione-S transferase-PAK4 S474D exhibited no evidence of resistance to PAK4i inhibition (data not shown). Taken together, these data suggest that E329K somatic mutation of the PAK4 kinase domain confers resistance to inhibition with competitive ATP inhibitors. Indeed, IC 50 values for PAK4i were calculated as B0.45 mM and B0.65 mM for wild-type PAK4 and PAK4 E329K , respectively, (Supplementary Figure S2) . Although mutations conferring resistance to tyrosine kinase inhibitors are well established, less is known about the development of resistance to inhibitors of serine/threonine kinases. Girdler et al. 36 recently reported the induction of drug-resistant mutations in aurora For inhibitor experiments, 0.5 or 10 mM purvalanol A or 1 or 5 mM PAK4i was added to the kinase buffer. The reaction was stopped by adding SDS-PAGE loading buffer. Autoradiographs and western blots were quantified using Andor IQ software (Belfast, UK) and the level of phosphorylation normalised to GST-protein levels. Phosphorylation of histone and autophosphorylation are indicated by arrows. Retained purified PAK4 proteins were subjected to GST immunoblotting to monitor expression levels (input). (a, c) PAK4 autophosphorylation and histone phosphorylation relative to wild-type PAK4 without purvalanol A ± s.e.m. (b) or without PAK4i (d) ± s.e.m. from five and four separate experiments, respectively. (e) 293 Cells over-expressing GFP, GFP-PAK4 or GFP-PAK4 E329K were lysed and endogenous LIMK1 was immunoprecipitated from lysates using an anti-LIMK1 antibody (BD Biosciences, Oxford, UK). IP blots were then probed for Phospho-LIMK1/2 (Cell Signaling Technology, Hitchin, UK) and re-probed for total LIMK (BD Biosciences). Whole cell lysates were probed for the level of PAK4 and PAK4 E329K expression using an anti-GFP antibody (Roche). Statistical significance was calculated using Student's t-test, *Po0.05.
kinase by treatment of cells with inhibitors. PAK4 E329K may therefore prove an important tool in aiding drug design and development, but also highlights the importance of developing multiple and alternative therapeutic strategies (for example, allosteric PAK inhibitors 21 ) to offset the risks associated with clinical drug resistance.
